Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01849874




Registration number
NCT01849874
Ethics application status
Date submitted
6/05/2013
Date registered
9/05/2013
Date last updated
30/10/2023

Titles & IDs
Public title
A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
Scientific title
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
Secondary ID [1] 0 0
C4211003
Secondary ID [2] 0 0
ARRAY-162-311
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Low-grade Serous Ovarian Cancer 0 0
Low-grade Serous Fallopian Tube Cancer 0 0
Low-grade Serous Peritoneal Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Ovarian and primary peritoneal
Cancer 0 0 0 0
Womb (Uterine or endometrial cancer)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - MEK162, MEK inhibitor; oral
Treatment: Drugs - Physician's choice chemotherapy

Experimental: MEK162 -

Active comparator: Physician's choice chemotherapy -


Treatment: Drugs: MEK162, MEK inhibitor; oral
multiple dose, single schedule

Treatment: Drugs: Physician's choice chemotherapy
Patients will receive one of the following chemotherapies as determined by the physician:

* Liposomal doxorubicin, anthracycline antibiotic; intravenous (multiple dose, single schedule)
* Paclitaxel, mitotic inhibitor; intravenous (multiple dose, single schedule)
* Topotecan, topoisomerase 1 inhibitor; intravenous (multiple dose, single schedule)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
Timepoint [1] 0 0
From randomization until documented progressive disease (PD) or death, whichever occurred first, for censored participants at the date of last adequate tumor assessment (up to 24 months)
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
From randomization date to the date of death, for censored participants at their last contact date (up to 24 months)
Secondary outcome [2] 0 0
Objective Response Rate Per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 (RECIST V1.1)
Timepoint [2] 0 0
From randomization until disease progression or death (up to 24 months)
Secondary outcome [3] 0 0
Duration of Response (DOR)
Timepoint [3] 0 0
From the first radiographic evidence of response to the first documentation of PD or death, for censored participants at their last radiological assessment (up to 24 months)
Secondary outcome [4] 0 0
Disease Control Rate (DCR)
Timepoint [4] 0 0
Week 24
Secondary outcome [5] 0 0
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timepoint [5] 0 0
From the first dose of study intervention until 30 days after the last dose (up to 9 years)
Secondary outcome [6] 0 0
Number of Participants With Shift Greater Than or Equal to Grade 3 From Baseline in Laboratory Parameter Values Based on National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03
Timepoint [6] 0 0
From the first dose of study intervention until 30 days after the last dose (up to 9 years)
Secondary outcome [7] 0 0
Quality of Life Per European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30)
Timepoint [7] 0 0
Screening, every 8 weeks from randomization for the first 72 weeks (while on treatment), treatment discontinuation visit, 30-day safety follow-up visit
Secondary outcome [8] 0 0
Quality of Life Per European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Ovarian Cancer Module (QLQ-OV28)
Timepoint [8] 0 0
Screening, every 8 weeks from randomization for the first 72 weeks (while on treatment), treatment discontinuation visit, 30-day safety follow-up visit
Secondary outcome [9] 0 0
Quality of Life Per Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-NTX)
Timepoint [9] 0 0
Screening, every 8 weeks from randomization for the first 72 weeks (while on treatment), treatment discontinuation visit, 30-day safety follow-up visit
Secondary outcome [10] 0 0
Predose Plasma Concentration (Ctrough) of MEK162
Timepoint [10] 0 0
Predose on Study Days 1, 57, and 113.
Secondary outcome [11] 0 0
Maximum Observed Plasma Concentration (Cmax) of MEK162
Timepoint [11] 0 0
2 hours ± 10 minutes postdose on Study Days 1, 57, and 113.

Eligibility
Key inclusion criteria
Key

* Diagnosis of LGS carcinoma of the ovary, fallopian tube or primary peritoneum (invasive micropapillary serous carcinoma or invasive grade 1 serous carcinoma), confirmed histologically and verified by central pathology review.
* Recurrent or persistent measurable disease that has progressed (defined as radiological and/or clinical progression; an increase in cancer antigen [CA]-125 alone is not sufficient) on or after last therapy (i.e., chemotherapy, hormonal therapy, surgery) and is not amenable to potentially curative intent surgery, as determined by the patient's treating physician.
* Must have received at least 1 prior platinum-based chemotherapy regimen but have received no more than 3 lines of prior chemotherapy regimens, with no limit to the number of lines of prior hormonal therapy. Front-line therapy may include neoadjuvant and adjuvant therapy and will be counted as 1 prior systemic regimen. Biological therapy (e.g. bevacizumab) administered as a single agent is considered a prior systemic regimen and not a prior chemotherapy regimen. Maintenance therapy is not considered its own regimen but should be included with the regimen that it follows.
* Available archival tumor sample (excisional or core biopsy) for confirmation of LGS carcinoma diagnosis. If adequate archival tumor sample is not available, willingness to consent to tissue biopsy.
* Suitable for treatment with at least one of the physician's choice chemotherapy options (liposomal doxorubicin, paclitaxel or topotecan) as determined by the Investigator.
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
* Additional criteria exist.

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
* History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes).
* Prior therapy with a MEK or BRAF inhibitor.
* History of Gilbert's syndrome.
* Impaired cardiovascular function or clinically significant cardiovascular diseases.
* Uncontrolled or symptomatic brain metastases that are not stable or require steroids, are potentially life-threatening or have required radiation within 28 days prior to first dose of study treatment.
* Concomitant malignancies or previous malignancies with less than a 5-year disease-free interval at the time of first dose of study treatment; patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or ductal carcinoma in situ may be enrolled irrespective of the time of diagnosis.
* Known positive serology for the human immunodeficiency virus (HIV), active hepatitis B and/or active hepatitis C.
* Prior randomization into this clinical study.
* Additional criteria exist.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/06/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
23/08/2022
Sample size
Target
Accrual to date
Final
341
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Dr Anil Arora - Wahroonga
Recruitment hospital [2] 0 0
Sydney Adventist Hospital - Wahroonga
Recruitment hospital [3] 0 0
Westmead Hospital - Westmead
Recruitment hospital [4] 0 0
Mater Misericordiae Health Services Brisbane Limited - South Brisbane
Recruitment hospital [5] 0 0
Adelaide Cardiology - Adelaide
Recruitment hospital [6] 0 0
Adelaide Eye and Retina Centre - Adelaide
Recruitment hospital [7] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [8] 0 0
Thomas and Delaney Optometrists - Norwood
Recruitment hospital [9] 0 0
Burnside War Memorial Hospital - Toorak Gardens
Recruitment hospital [10] 0 0
Sunshine Hospital - St Albans
Recruitment hospital [11] 0 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment postcode(s) [1] 0 0
2076 - Wahroonga
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
4101 - South Brisbane
Recruitment postcode(s) [4] 0 0
5000 - Adelaide
Recruitment postcode(s) [5] 0 0
5067 - Norwood
Recruitment postcode(s) [6] 0 0
5065 - Toorak Gardens
Recruitment postcode(s) [7] 0 0
3021 - St Albans
Recruitment postcode(s) [8] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
Montana
Country [15] 0 0
United States of America
State/province [15] 0 0
New Mexico
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oklahoma
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Virginia
Country [22] 0 0
Austria
State/province [22] 0 0
Tirol
Country [23] 0 0
Belgium
State/province [23] 0 0
Luxembourg
Country [24] 0 0
Belgium
State/province [24] 0 0
Vlaams-brabant
Country [25] 0 0
Belgium
State/province [25] 0 0
Brussels
Country [26] 0 0
Belgium
State/province [26] 0 0
Gent
Country [27] 0 0
Belgium
State/province [27] 0 0
Liege
Country [28] 0 0
Belgium
State/province [28] 0 0
Namur
Country [29] 0 0
Belgium
State/province [29] 0 0
Wilrijk
Country [30] 0 0
Canada
State/province [30] 0 0
Alberta
Country [31] 0 0
Canada
State/province [31] 0 0
British Columbia
Country [32] 0 0
Canada
State/province [32] 0 0
Manitoba
Country [33] 0 0
Canada
State/province [33] 0 0
Ontario
Country [34] 0 0
Canada
State/province [34] 0 0
Quebec
Country [35] 0 0
Czechia
State/province [35] 0 0
Hradec Kralove
Country [36] 0 0
Czechia
State/province [36] 0 0
Olomouc
Country [37] 0 0
Czechia
State/province [37] 0 0
Ostrava - Poruba
Country [38] 0 0
Czechia
State/province [38] 0 0
Ostrava-Poruba
Country [39] 0 0
Czechia
State/province [39] 0 0
Prague 2
Country [40] 0 0
Czechia
State/province [40] 0 0
Prague
Country [41] 0 0
Denmark
State/province [41] 0 0
North Jutland
Country [42] 0 0
Denmark
State/province [42] 0 0
Herlev
Country [43] 0 0
Denmark
State/province [43] 0 0
Kobenhavn o
Country [44] 0 0
Denmark
State/province [44] 0 0
København Ø
Country [45] 0 0
Finland
State/province [45] 0 0
Tampere
Country [46] 0 0
France
State/province [46] 0 0
Besancon
Country [47] 0 0
France
State/province [47] 0 0
Lille
Country [48] 0 0
France
State/province [48] 0 0
LYON Cedex 08
Country [49] 0 0
France
State/province [49] 0 0
Lyon
Country [50] 0 0
France
State/province [50] 0 0
Marseille Cedex 09
Country [51] 0 0
France
State/province [51] 0 0
Marseille
Country [52] 0 0
France
State/province [52] 0 0
Montferrier S/lez
Country [53] 0 0
France
State/province [53] 0 0
Montpellier CEDEX 5
Country [54] 0 0
France
State/province [54] 0 0
NANTES Cedex 2
Country [55] 0 0
France
State/province [55] 0 0
Nantes
Country [56] 0 0
France
State/province [56] 0 0
Paris Cedex 15
Country [57] 0 0
France
State/province [57] 0 0
Paris
Country [58] 0 0
France
State/province [58] 0 0
Plerin
Country [59] 0 0
France
State/province [59] 0 0
Saint-Herblain Cedex
Country [60] 0 0
France
State/province [60] 0 0
Villejuif Cedex
Country [61] 0 0
Germany
State/province [61] 0 0
Baden-wuerttemberg
Country [62] 0 0
Germany
State/province [62] 0 0
Baden-wurttemberg
Country [63] 0 0
Germany
State/province [63] 0 0
Bavaria
Country [64] 0 0
Germany
State/province [64] 0 0
Hessen
Country [65] 0 0
Germany
State/province [65] 0 0
North Rhine-westphalia
Country [66] 0 0
Germany
State/province [66] 0 0
North-rhine Westphalia
Country [67] 0 0
Germany
State/province [67] 0 0
Saxony
Country [68] 0 0
Germany
State/province [68] 0 0
Schleswig-holstein
Country [69] 0 0
Germany
State/province [69] 0 0
Berlin
Country [70] 0 0
Germany
State/province [70] 0 0
Freiburg
Country [71] 0 0
Germany
State/province [71] 0 0
Greifswald
Country [72] 0 0
Germany
State/province [72] 0 0
Heidelberg
Country [73] 0 0
Hungary
State/province [73] 0 0
Gyor-moson-sopron
Country [74] 0 0
Hungary
State/province [74] 0 0
Budapest
Country [75] 0 0
Ireland
State/province [75] 0 0
Dublin 8
Country [76] 0 0
Italy
State/province [76] 0 0
Milano
Country [77] 0 0
Italy
State/province [77] 0 0
Pordenone
Country [78] 0 0
Italy
State/province [78] 0 0
Ravenna
Country [79] 0 0
Italy
State/province [79] 0 0
RM
Country [80] 0 0
Italy
State/province [80] 0 0
Rome
Country [81] 0 0
Italy
State/province [81] 0 0
Bologna
Country [82] 0 0
Italy
State/province [82] 0 0
Brescia
Country [83] 0 0
Italy
State/province [83] 0 0
Catania
Country [84] 0 0
Italy
State/province [84] 0 0
Napoli
Country [85] 0 0
Italy
State/province [85] 0 0
Roma
Country [86] 0 0
Netherlands
State/province [86] 0 0
Noord-holland
Country [87] 0 0
Netherlands
State/province [87] 0 0
Groningen
Country [88] 0 0
Netherlands
State/province [88] 0 0
Maastricht
Country [89] 0 0
Norway
State/province [89] 0 0
Oslo
Country [90] 0 0
Poland
State/province [90] 0 0
Warsaw
Country [91] 0 0
Spain
State/province [91] 0 0
Barcelona
Country [92] 0 0
Spain
State/province [92] 0 0
Castilla LA Mancha
Country [93] 0 0
Spain
State/province [93] 0 0
Guipuzcoa
Country [94] 0 0
Spain
State/province [94] 0 0
Cordoba
Country [95] 0 0
Spain
State/province [95] 0 0
L'Hospitalet de Llobregat
Country [96] 0 0
Spain
State/province [96] 0 0
Madrid
Country [97] 0 0
Spain
State/province [97] 0 0
Palma de Mallorca
Country [98] 0 0
Spain
State/province [98] 0 0
Sevilla
Country [99] 0 0
Spain
State/province [99] 0 0
Toledo
Country [100] 0 0
Spain
State/province [100] 0 0
Valencia
Country [101] 0 0
Sweden
State/province [101] 0 0
Stockholm
Country [102] 0 0
Sweden
State/province [102] 0 0
Uppsala
Country [103] 0 0
United Kingdom
State/province [103] 0 0
England
Country [104] 0 0
United Kingdom
State/province [104] 0 0
Nottinghamshire
Country [105] 0 0
United Kingdom
State/province [105] 0 0
Surrey
Country [106] 0 0
United Kingdom
State/province [106] 0 0
Sutton
Country [107] 0 0
United Kingdom
State/province [107] 0 0
WEST Midlands
Country [108] 0 0
United Kingdom
State/province [108] 0 0
London
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer) is a Phase 3 study during which patients with recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum will receive either investigational study drug MEK162 or a chemotherapy chosen by the physician (liposomal doxorubicin, paclitaxel or topotecan). Patients will be followed to compare the effectiveness of the study drug to that of the selected chemotherapies. Patients may be eligible to crossover from physician's choice chemotherapy to MEK162 if they meet certain inclusion criteria including centrally confirmed disease progression. Approximately 360 patients from North America, Europe and Australia will be enrolled in this study.
Trial website
https://clinicaltrials.gov/study/NCT01849874
Trial related presentations / publications
Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Boyd AP, Kristensen G, Clamp A, Ray-Coquard I, Vergote I. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. J Clin Oncol. 2020 Nov 10;38(32):3753-3762. doi: 10.1200/JCO.20.01164. Epub 2020 Aug 21.
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01849874